Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tevogen Bio Holdings Inc. - Common Stock (NQ:TVGN)

0.6663 +0.0303 (+4.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 224,382
Open 0.6400
Bid (Size) 0.6588 (7)
Ask (Size) 0.6800 (91)
Prev. Close 0.6360
Today's Range 0.6400 - 0.6663
52wk Range 0.6100 - 3.090
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
From Tevogen Bio Inc
Via GlobeNewswire

Performance

YTD
-37.1%
-37.1%
1 Month
-15.1%
-15.1%
3 Month
-38.3%
-38.3%
6 Month
-28.9%
-28.9%
1 Year
-78.2%
-78.2%

More News

Read More
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
From Tevogen Bio Inc
Via GlobeNewswire
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen CEO Donates Personal Shares to Support Local Law Enforcement
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected
From Tevogen Bio Inc
Via GlobeNewswire
Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
From Tevogen Bio Inc
Via GlobeNewswire
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
From Tevogen Bio Inc
Via GlobeNewswire
Unusual volume stocks in Monday's session
Via Chartmill
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
From Tevogen Bio Inc
Via GlobeNewswire
REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
From Tevogen Bio Inc
Via GlobeNewswire
REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
From Tevogen Bio Inc
Via GlobeNewswire

Frequently Asked Questions

Is Tevogen Bio Holdings Inc. - Common Stock publicly traded?
Yes, Tevogen Bio Holdings Inc. - Common Stock is publicly traded.
What exchange does Tevogen Bio Holdings Inc. - Common Stock trade on?
Tevogen Bio Holdings Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tevogen Bio Holdings Inc. - Common Stock?
The ticker symbol for Tevogen Bio Holdings Inc. - Common Stock is TVGN on the Nasdaq Stock Market
What is the current price of Tevogen Bio Holdings Inc. - Common Stock?
The current price of Tevogen Bio Holdings Inc. - Common Stock is 0.6663
When was Tevogen Bio Holdings Inc. - Common Stock last traded?
The last trade of Tevogen Bio Holdings Inc. - Common Stock was at 10/24/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.